Hong Koh

Hong Koh

Auto-generated profile, based on publicly available information

Hong Koh


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
OWOrith Waisbourd‐Zinman
Orith Waisbourd‐Zinman
HKHong Koh
Hong Koh
STShannon Tsai
Shannon Tsai
PLPierre‐Marie Lavrut
Pierre‐Marie Lavrut
CDChristine Dang
Christine Dang
RWRebecca G. G. Wells
Rebecca G. G. Wells
Biliary atresia, the most common indication for pediatric liver transplantation, is a fibrotic disease of unknown etiology affecting the extrahepatic bile ducts of newborns. The recently described toxin biliatresone causes lumen obstruction in mouse cholangiocyte spheroids and represents a new model of biliary atresia. The goal of this study was to determine the cellular changes caused by biliatresone in mammalian cells that ultimately lead to biliary atresia and extrahepatic fibrosis. We treated mouse cholangiocytes in three‐dimensional (3D) spheroid culture and neonatal extrahepatic duct explants with biliatresone and compounds that regulate glutathione (GSH). We examined the effects of biliatresone on SOX17 levels and determined the effects of Sox17 knockdown on cholangiocytes in 3D culture. We found that biliatresone caused disruption of cholangiocyte apical polarity and loss of monolayer integrity. Spheroids treated with biliatresone had increased permeability as shown by rhodamine efflux within 5 hours compared with untreated spheroids, which retained rhodamine for longer than 12 hours. Neonatal bile duct explants treated with the toxin showed lumen obstruction with increased subepithelial staining for α‐smooth muscle actin and collagen, consistent with fibrosis. Biliatresone caused a rapid and transient decrease in GSH, which was both necessary and sufficient to mediate its effects in cholangiocyte spheroid and bile duct explant systems. It also caused a significant decrease in cholangiocyte levels of SOX17, and Sox17 knockdown in cholangiocyte spheroids mimicked the effects of biliatresone. Conclusion: Biliatresone decreases GSH and SOX17 in mouse cholangiocytes. In 3D cell systems, this leads to cholangiocyte monolayer damage and increased permeability; in extrahepatic bile duct explants, it leads to disruption of the extrahepatic biliary tree and subepithelial fibrosis. This mechanism may be important in understanding human biliary atresia. (Hepatology 2016;64:880‐893)

7 July 2020 in Micromachines
Verified
Journal Article
Open access
PDF file
YSYong Cheol Shin
Yong Cheol Shin
WSWoojung Shin
Woojung Shin
DKDomin Koh
Domin Koh
AWAlexander Wu
Alexander Wu
YAYoko M. Ambrosini
Yoko M. Ambrosini
Hyun Jung KimHyun Jung Kim
Hyun Jung Kim
The regeneration of the mucosal interface of the human intestine is critical in the host–gut microbiome crosstalk associated with gastrointestinal diseases. The biopsy-derived intestinal organoids provide genetic information of patients with physiological cytodifferentiation. However, the enclosed lumen and static culture condition substantially limit the utility of patient-derived organoids for microbiome-associated disease modeling. Here, we report a patient-specific three-dimensional (3D) physiodynamic mucosal interface-on-a-chip (PMI Chip) that provides a microphysiological intestinal milieu under defined biomechanics. The real-time imaging and computational simulation of the PMI Chip verified the recapitulation of non-linear luminal and microvascular flow that simulates the hydrodynamics in a living human gut. The multiaxial deformations in a convoluted microchannel not only induced dynamic cell strains but also enhanced particle mixing in the lumen microchannel. Under this physiodynamic condition, an organoid-derived epithelium obtained from the patients diagnosed with Crohn’s disease, ulcerative colitis, or colorectal cancer independently formed 3D epithelial layers with disease-specific differentiations. Moreover, co-culture with the human fecal microbiome in an anoxic–oxic interface resulted in the formation of stochastic microcolonies without a loss of epithelial barrier function. We envision that the patient-specific PMI Chip that conveys genetic, epigenetic, and environmental factors of individual patients will potentially demonstrate the pathophysiological dynamics and complex host–microbiome crosstalk to target a patient-specific disease modeling.

1 August 2010 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SKSang Yong Kim
Sang Yong Kim
JSJae Yeon Seok
Jae Yeon Seok
SHSeok Joo Han
Seok Joo Han
HKHong Koh
Hong Koh

15 April 2019 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
JSJaeseung Shin
Jaeseung Shin
MKMyung-Joon Kim
Myung-Joon Kim
HSHyun Joo Shin
Hyun Joo Shin
HYHaesung Yoon
Haesung Yoon
SKSeung Kim
Seung Kim
MLMi-Jung Lee
Mi-Jung Lee
Controlled attenuation parameter (CAP) is a recently introduced, non-invasive and quantitative method to evaluate hepatic steatosis demonstrated in adults, but limited in obesity and not well evaluated in children. The aim of this study was to investigate the diagnostic performance for assessing hepatic steatosis grades using CAP in children based on MR proton density fat fraction (PDFF). Children evaluated for non-alcoholic fatty liver disease (NAFLD) who were assessed for PDFF and CAP were enrolled retrospectively. Hepatic steatosis grades 0–3 were classified according to PDFF using cutoff values of 6, 17.5, and 23.3%. Subgroup analyses were performed in non-obese and obese groups using the 95th percentile body mass index (BMI) as a cutoff and BMI30 group when BMI > 30 kg/m2. Pearson’s correlations between variables were also analyzed. In a total of 86 children, there were 53 in the obese group including 17 of the BMI30 group. CAP demonstrated 98.7% sensitivity and 80% specificity for diagnosing grades 1–3 vs. grade 0 using a cutoff value of 241 dB/m (area under the curve = 0.941, p < 0.001). The diagnostic performance for higher steatosis grades was suboptimal. CAP correlated with abdominal wall thickness in both obese (r = 0.549, p = 0.001) and non-obese (r = 0.386, p = 0.004) groups and did not correlate with PDFF in BMI30 group. In children with NAFLD, CAP showed excellent diagnostic performance for differentiating presence and absence of hepatic steatosis using a cutoff value of 241 dB/m. However, CAP was limited in evaluating grades of steatosis, especially in children with BMI > 30 kg/m2.

1 May 2014 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
NSNa-Young Shin
Na-Young Shin
MKMyung-Joon Kim
Myung-Joon Kim
MLMi-Jung Lee
Mi-Jung Lee
SHSeok Joo Han
Seok Joo Han
HKHong Koh
Hong Koh
YPYoung Nyun Park
Young Nyun Park

5 June 2019 in Critical Reviews in Environmental Science and Technology
Verified
Journal Article
Closed access
NKNAM JOO KANG
NAM JOO KANG
HJHyeon-Su Jin
Hyeon-Su Jin
Sung-Eun LeeSung-Eun Lee
Sung-Eun Lee
Hyun Jung KimHyun Jung Kim
Hyun Jung Kim
HKHong Koh
Hong Koh
DLDong-Woo Lee
Dong-Woo Lee
Bioactive peptides (BPs) play key roles in regulating cellular metabolism, and are therefore of special interest to the nutraceutical and pharmaceutical industries. Protein digestion is a major route to production of BPs. Biocatalyst-aided processes are advantageous in that they generate protein hydrolysates with high specificity that are non-immunogenic and resistant to proteolysis in the gastrointestinal tract. On the other hand, these approaches are limited by their high production cost and poor diversity of peptides, as well as the requirement for sophisticated analysis for functional validation and scale-up. The recent development of microbial genome and protein databases, together with in silico analysis, have enabled BP design with bioavailability and the identification of new routes for the isolation of BPs from natural resources. In this review, we focus on recent developments in native BP targeting informatics, novel microbial protease mining, and screening methods, which together will accelerate the development of genome-based microbial routes to therapeutic BPs that promote human health and nutrition.